Currently around 1 million coronary artery bypass grafting (CABG) operations are performed annually worldwide. In comparison to stents, CABG offers a marked survival benefit accompanied by a significant reduction in myocardial infarction and repeat revascularization for more advanced coronary artery disease. The standard operation worldwide is to use a single internal thoracic artery (ITA) and additional vein grafts as most patients require three bypass grafts. The long-term benefits of CABG beyond 10 years may however be nullified by progressive vein graft failure.
To address the potential benefit of a second arterial graft, 3102 patients were randomized to single or bilateral ITA grafts. With an impressive 98% completeness of follow-up at 10 years, the Arterial Revascularization Trial (ART) has the largest sample size with the longest follow-up in the history of cardiac surgical trials ( Figure 1) . ART is arguably the most important trial (or one of the two most important at least) ever performed in cardiac surgery. As CABG is the most commonly performed cardiac surgical procedure in the adult, 1 the possibility that one surgical strategy may significantly improve its results has enormous implications for patients and society. The mechanisms of vein graft failure have been only in part elucidated. During the first post-operative year, excluding technical errors, the main cause of occlusion is intimal hyperplasia. 2 This process is probably exacerbated by inflammatory cytokines 3 and has recently been found to be modulated by microRNA-33. 4 After the first year, the development of atherosclerosis is the single most important reason of graft dysfunction and failure. 5 The atherosclerotic process observed in bypass grafts has some similarities to that observed in coronary arteries but is in general more aggressive and extensive. Arterial grafts as opposed to saphenous vein grafts have been shown to be more resistant to the development of atherosclerosis, probably due to the peculiar morphological and functional features of arterial conduits. 5 In addition, arterial grafts, by eluting beneficial vasoactive agents, have been suggested to protect the distal native coronary bed from the progression of disease. The role of arterial conduits for CABG has been debated for more than four decades. 6 In observational studies, the use of multiple arterial grafts is generally associated with longer survival and better quality of life after surgery. 7 The documented superior patency rate of arterial grafts compared to saphenous vein grafts is usually considered the biologic rationale for this association. However, an alternative explanation is that surgeons use multiple arterial grafts (technically more complex and time consuming) in healthier patients with perceived longer life expectancy. There is evidence that treatment allocation bias, and not biologic superiority, may potentially explain the survival difference in observational studies comparing the use of one vs. two ITAs (SITA vs. BITA, respectively). 8 By eliminating the potential for selection bias and differences in treatment allocation, randomized trials are the only way to provide a scientifically solid answer to the four-decade old arterial graft controversy. Before ART, only three small randomized trials had compared the use of SITA and BITA. 7 All of them were clearly underpowered to detect even moderate differences in outcomes.
ART was conceived and designed to finally test the arterial graft superiority hypothesis in an appropriately powered randomized trial. From 2004 to 2007, the ART investigators randomized 3102 patients in 28 centres and 7 countries to SITA and BITA. The primary outcome was overall survival; ART has 90% power to detect a 20% relative risk reduction (from 25% to 20%) at 10-year follow-up.
The final results of ART have been eagerly awaited by the cardiac surgery and cardiology community for more than 15 years. Notably, they have been presented at the 2018 annual meeting of the European Society of Cardiology, exactly 50 years after the first systematic description of CABG by Renee Favaloro, also known as the father of coronary surgery. 9 At 10 years, there was no difference in survival and event-free survival between the two groups in the intention-to-treat (ITT) analysis.
Surgical trials however have unique challenges and complexity. The ART investigators correctly highlight that two important confounders may have played a major role in determining the results of the ITT analysis:
(1) The high number of crossover from BITA to SITA (14% of the patients did not in fact receive the assigned second ITA). The high crossover rate obviously dilutes the potential treatment effect. Crossover is known to be related to surgeons experience with the procedure 10 and the high rate of crossover questions the level of comfort of some ART surgeons in performing the BITA operation. Biases due to surgical factors and suboptimal technical execution of the experimental procedure may possibly explain the lack of BITA effect. ART may be measuring not the efficacy but the deliverability of the BITA. Indeed, in the ITT analysis a clear volume-outcome relation was noted, with high enroller surgeons having results significantly in favour of the BITA arm. This observation reinforces the hypothesis of the technical factor as key to the neutral results of ART. (2) The frequent use of radial artery (RA) grafts. In ART, the use of a complementary arterial or venous conduit was left to the discretion of the operating surgeon. As a result, 22% of patients in the SITA group received a RA. This co-intervention is particularly important as we now know that the use of the RA instead of the saphenous vein is associated with significant clinical benefits for CABG patients. 11 The frequent use of another arterial conduit in the control group may also have diluted the BITA treatment effect. Both the high crossover and the high co-intervention rate in ART play in favour of the null hypothesis and it is conceivable that methodological issues, and not lack of biological effect, may explain the neutral results of the trial. To shed some light on this possibility, the ART investigators performed an additional, not pre-specified post hoc analysis comparing patients who received single vs. multiple arterial grafts (categorizing patients who received BITA or SITA and RA in the same multiarterial group). 12 In this explanatory analysis, a significant difference was found in both survival and event-free survival in favour of the use of multiple arterial grafts. Clearly, post hoc exploratory analyses have important intrinsic limitations. They are observational comparisons and suffer from the same potential methodological flaws that we have already described. On the other hand, the ART explanatory analysis has a solid biologic rationale (the better patency rate of arterial grafts and the described superior outcome of patients receiving the RA instead of the saphenous vein). Also, by being based on prospectively collected data from a rigorous trial, the ART post hoc analysis is likely of higher quality compared to traditional observational registries and has more solid adjustment for confounders.
With this in mind, the ART investigators correctly underline that, as the results of the ITT analysis are neutral, the results of ancillary comparisons must be viewed as preliminary and hypothesis generating.
Currently another trial, the Randomized comparison of the Outcome of single vs. Multiple Arterial grafts (ROMA) trial is testing the hypothesis generated by the post hoc analysis of ART. ROMA is designed to compare the clinical outcomes of patients receiving one vs. multiple arterial grafts. The use of either BITA or LITA and RA is allowed in the multiarterial group (no supplementary arterial grafts are used in the control group). 13 ROMA has been designed to take into account the methodological challenges and lessons learned from to the ART investigators. In this sense, ART has opened the path that ROMA now has started walking.
While we await the results of ROMA (estimated in 2025), the choice of conduits in coronary surgery is still a matter of experience, clinical judgement and, most importantly, tailoring of the operation to the individual patient and surgeon. Still more ART than science . . .
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